AR and pachyonychia congenita: In metastatic samples, the study also specifically explores if promoter methylation levels are related to the sample AR activity, defined from transcript levels of genes recently described to differentiate clinically relevant molecular subtypes of PC bone metastases based on AR activity [9, 10, 12].